Clinical Trial Update: Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nivolumab with tadalafil and oral vancomycin in patients with refractory hepatocellular carcinoma or liver-dominant metastases…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Hepatocellular Carcinoma
• Pancreatic Cancer

Drugs mentioned

• TADALAFIL (TADALAFIL)
• Vancomycin (vancomycin)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-07-11